Stability Testing for FDA Approved KSHNO14 (Pyridostigmine Bromide Extend – Release Tablets)
| Agency: | DEPT OF DEFENSE |
|---|---|
| State: | Maryland |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Posted Date: | Jan 29, 2026 |
| Due Date: | Feb 19, 2026 |
| Solicitation No: | W911SR-26-S-ASPC |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Sources Sought (Original)
- Original Published Date: Jan 29, 2026 07:57 am EST
- Original Response Date: Feb 19, 2026 02:00 pm EST
- Inactive Policy: 15 days after response date
- Original Inactive Date: Mar 06, 2026
-
Initiative:
- None
- Original Set Aside:
- Product Service Code: AC13 - NATIONAL DEFENSE R&D SERVICES; DEPARTMENT OF DEFENSE - MILITARY; EXPERIMENTAL DEVELOPMENT
-
NAICS Code:
- 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
-
Place of Performance:
MD 21702USA
This Sources Sought notice is issued for market research purposes only to identify potential sources capable of supporting FDA compliant stability testing for FDA approved KSHN014 (Pyridostigmine Bromide Extend – Release Tablets) 105 mg tablet for five (5) years at CRT and ten (10) years refrigerated, manufactured by Amneal Complex Research LLC and packaged in Blister Pack throughout the in-use period.
The government is specifically seeking information on vendors capable of assuming or supporting long term stability testing including continued continuity requirements associated with an existing ongoing stability study. This notice is not a solicitation for proposals, and no award will be made as a result of this notice.
CPE CBRN Medical CDP has an ongoing stability study in support of FDA approved KSHN014 (Pyridostigmine Bromide Extend – Release Tablets) 105 mg tablets, the study includes multiyear stability testing including long term and refrigerated storage conditions with stability data.
The government is conducting market research to determine whether there are additional responsible sources capable of meeting the full scope of technical regulatory and continuity requirements associated with this effort.
- EDGEWOOD DIVISION 8456 BRIGADE STREET
- ABERDEEN PROVING GROU , MD 21010-5424
- USA
- Scott Hoffman
- scott.i.hoffman2.civ@army.mil
- Mea Johnson
- mea.n.johnson.civ@army.mil
- Jan 29, 2026 07:57 am ESTSources Sought (Original)
See Also
Follow Generative Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and
DEPT OF DEFENSE
Due by 10/18/2028
Follow Strategic Contract Consolidation Announcement Active Contract Opportunity Notice ID Command_Control_and_Information_Network_(CPE_C2IN) Related Notice
DEPT OF DEFENSE
Follow Notice of Intent to Sole Source the Co-sponsorship of a Forum on
DEPT OF DEFENSE
Due by 11/18/2026
ID: BPM059686 Title: RFA: Maryland Pediatric Cancer Fund Research Grants Status: Open Due
State Government of Maryland
Due by 1/29/2027